Bioasis Technologies and Chiesi Global Rare Diseases have entered into a worldwide, exclusive licensing agreement re the Bioasis platform technology, with a focus on four undisclosed lysosomal storage disorders.
Bioasis is a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier and for the treatment of central nervous system disorders.